Cybin (HELP) Non Operating Income (2020 - 2026)
Cybin's (HELP) quarterly Non Operating Income came in at $864000.0 in Q1 2026, down 53.94% YoY from $1.9 million in Q1 2025, and up 159.26% on a QoQ basis from -$1.5 million in Q4 2025.
Cybin (HELP) Non Operating Income (2020 - 2026) Analysis & Trends
Cybin (HELP) has 7 years of Non Operating Income data on file, last reported at $864000.0 in Q1 2026.
- Quarterly Non Operating Income fell 53.94% year-over-year to $864000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (down 130.91% YoY) and the FY2026 annual result came in at -$5.4 million, down 125.15% from the prior year.
- Non Operating Income climbed to $864000.0 in Q1 2026, from -$1.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $14.8 million in Q4 2024 to a low of -$4.8 million in Q3 2025.
- A 5-year average of $818489.7 and a median of $2354.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 611579.01% — and 2025, when it sank 720.57%.
- Tracing HELP's Non Operating Income over 5 years: stood at $1351.0 in 2022, then tumbled by 279.75% to -$2428.4 in 2023, then soared by 611579.01% to $14.8 million in 2024, then sank by 109.82% to -$1.5 million in 2025, then soared by 159.26% to $864000.0 in 2026.
- The last three Non Operating Income figures came in at $864000.0 (Q1 2026), -$1.5 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | 864,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 864,000.00 |
| Dec 31, 2025 | -1.46 Mn |
| Sep 30, 2025 | -4.83 Mn |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 14.85 Mn |
| Sep 30, 2024 | 778,000.00 |
| Jun 30, 2024 | 5,493.00 |
| Dec 31, 2023 | -2,428.37 |
| Sep 30, 2023 | 1,506.78 |
| Jun 30, 2023 | -1.35 Mn |
| Feb 28, 2023 | 1.52 Mn |
| Dec 31, 2022 | 1,351.00 |
| Sep 30, 2022 | 2,354.00 |
| Mar 31, 2022 | -1,759.00 |
| Dec 31, 2021 | -755.00 |
| Sep 30, 2021 | -397,999.06 |
| Jun 30, 2021 | -632.92 |
| Mar 31, 2021 | -1,414.00 |
| Dec 31, 2020 | -30,682.19 |